Latanoprost gel for vitiligo in teens
Part of Skin clinical trials.
This study tests a gel containing latanoprost on vitiligo patches in teens. It aims to see if the gel can help restore skin color in stable, non-segmental vitiligo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 10 and 17 years old.
- You have non-segmental vitiligo (patches on both sides of your body).
- Your vitiligo has been stable (no new patches or spreading) for at least 6 months.
- Your vitiligo affects less than 10% of your body.
- You have at least two vitiligo patches of similar size (about 1 to 4 cm² each) on opposite sides of your body, and not on your palms, soles, or genitals.
- You have not used certain creams, pills, or light therapy for vitiligo recently (check with the study team for details).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatments for vitiligo: narrowband UVB light therapy combined with either tacrolimus ointment or calcipotriol ointment. It aims to see which combination works better and is safer for people with stable, limited vitiligo.
This trial tests a new treatment for non-segmental vitiligo that uses a special liquid made from stem cells, applied through tiny needle pricks or small injections, alongside standard light therapy. It may help restore pigment to white patches with fewer side effects than traditional treatments.
This study tests a cream called ruxolitinib for children with nonsegmental vitiligo. It aims to see if the cream can safely help restore skin color in affected areas.
This study tests a medicated foam (Roflumilast) in children with non-segmental vitiligo to see if it can improve skin color on the face and body. It is for patients aged 2 to 17 with small patches and at least some pigmented hair in the face patches.
This trial tests an ointment called MH004 to see if it helps repigment white patches in people with non-segmental vitiligo (the most common type). It focuses on patches on the face and body.
This trial tests a cream (ruxolitinib) combined with corticosteroid treatment for people with active, non-segmental vitiligo that affects the face. It aims to see how well this combination works in real-world settings.
Hear when a new Vitiligo - Macular Depigmentation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.